secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-04-21T23:59:59+00:00
Accession:  0001104659-26-046014
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics completes FDA dispute resolution meeting for ONS-5010; decision expected May 2026
--------------------------------------------------------------------------------

- Completed Federal Dispute Resolution meeting with FDA Office of New Drugs to appeal Dec 30, 2025 Complete Response Letter for ONS-5010 BLA.
- Meeting addressed regulatory pathway for ONS-5010/LYTENAVA (bevacizumab-vikg) for wet AMD.
- Formal FDA decision expected in May 2026; company will update after receipt.
- Follows Type A meeting with Division of Ophthalmology; CEO Bob Jahr cites constructive dialogue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926046014/0001104659-26-046014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926046014/tm2612353d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-046014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer